Oryzon Genomics SA (ORY) AI Stock Analysis

• Market Cap: €204.25M
• Dividend Yield: N/A
• Average Volume (3M): 419.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: N/A
• EPS Growth: -2.02%
• Country: ES
• Employees: 47
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 78,547,620
• 10 Day Avg. Volume: 406,490
• 30 Day Avg. Volume: 419,019
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €12.00
• Price Target Upside: 368.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 54 Neutral
• Price Target: €3.00 ▲(17.19% Upside)

Oryzon Genomics SA's overall stock score is driven primarily by its financial performance and technical analysis. The company's strong equity position is a positive, but ongoing net losses and increasing leverage pose risks. Technical indicators suggest a lack of strong momentum. The negative P/E ratio highlights current unprofitability, and absence of dividends impacts investor appeal.

Oryzon Genomics SA Business Overview & Revenue Model

Company Description

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

How the Company Makes Money

Oryzon Genomics SA generates revenue primarily through collaborative agreements with other pharmaceutical companies, licensing its proprietary technology, and conducting research and development projects. The company forms strategic partnerships to co-develop and commercialize its drug candidates, which may involve upfront payments, milestone payments, and royalties on future sales. Oryzon also seeks funding through government grants and research subsidies to support its ongoing R&D efforts. These partnerships and collaborations are crucial for providing the financial resources needed to advance their clinical trial programs and ultimately bring their therapeutics to market.

Oryzon Genomics SA Financial Statement Overview

Summary

Oryzon Genomics SA is in a typical growth phase for a biotechnology company, showing high gross margins but facing consistent net losses and negative cash flows. Its strong equity position provides financial stability, although rising debt levels and continuous losses are concerning.

Income Statement

Oryzon Genomics SA shows improving revenue presence with a significant increase from zero in 2020 to 2024, however, revenue has declined in the past year. Gross profit margins are high, but the company is operating at a net loss, impacting the net profit margin and EBIT/EBITDA margins negatively. The company appears to be focusing on growth and development, typical for the biotechnology sector, yet consistent losses are a concern.

Balance Sheet

The balance sheet indicates a strong equity position with a high equity ratio, suggesting stability. However, the debt-to-equity ratio has increased slightly, indicating rising leverage. Return on equity is currently negative due to ongoing losses. Overall, the company maintains a solid asset base, but increasing debt levels should be monitored.

Cash Flow

Cash flows reveal consistent negative free cash flow, reflecting heavy investment and operating cash outflows. The operating cash flow to net income ratio is negative due to losses. Financing activities are positive, suggesting reliance on external funding. Continuous negative cash flow is a risk, but typical for growth-focused biotech firms.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.36M	14.19M	15.70M	10.62M	9.52M
Gross Profit	7.06M	13.95M	15.23M	9.87M	8.99M
EBITDA	-4.43M	-4.26M	-5.08M	-6.88M	-4.16M
Net Income	-3.67M	-3.35M	-4.23M	-4.69M	-3.40M
Balance Sheet
Total Assets	108.72M	106.90M	103.70M	95.38M	94.11M
Cash, Cash Equivalents and Short-Term Investments	5.62M	12.26M	21.32M	28.72M	39.60M
Total Debt	16.21M	13.69M	17.44M	13.77M	9.09M
Total Liabilities	21.67M	25.13M	31.13M	24.12M	18.18M
Stockholders Equity	87.04M	81.77M	72.57M	71.26M	75.93M
Cash Flow
Free Cash Flow	-5.69M	-15.08M	-16.12M	-15.39M	-14.04M
Operating Cash Flow	-5.69M	-574.96K	-1.85M	-3.63M	-4.82M
Investing Cash Flow	-7.81M	-14.50M	-14.27M	-11.72M	-9.08M
Financing Cash Flow	6.87M	6.02M	8.71M	4.12M	18.38M

Oryzon Genomics SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ORY, the sentiment is Negative. The current price of 2.56 is below the 20-day moving average (MA) of 2.74, below the 50-day MA of 2.76, and above the 200-day MA of 2.29, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 34.35 is Neutral, neither overbought nor oversold. The STOCH value of 8.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ES:ORY.

Oryzon Genomics SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ORY	54 Neutral	€204.25M	―	-4.53%	―	―	-2.02%
Sector *	51 Neutral	$7.37B	0.24	-62.86%	2.36%	15.01%	-2.64%
0RB1	―	€245.01M	36.58	3.04%	―	―	―
0ILL	―	€2.63B	20.07	25.44%	1.43%	―	―
PHMMF	―	$1.70B	35.34	21.61%	0.99%	―	―
041	―	€24.02M	―		―	―	―
A2T	―	€214.26M	―	-11.64%	―	―	―

Oryzon Genomics SA Corporate Events

Oryzon Genomics Advances Phase III Trial for BPD Treatment

Oryzon Genomics has submitted the protocol for its Phase III PORTICO-2 clinical trial to the FDA, aiming to evaluate the efficacy of vafidemstat in treating Borderline Personality Disorder (BPD). This trial is significant as it seeks to address the unmet medical need of reducing aggression in BPD patients, building on promising results from previous studies and marking a major advancement for both the company and the neuropsychiatry field.

The most recent analyst rating on (ES:ORY) stock is a Buy with a EUR2.30 price target. To see the full list of analyst forecasts on Oryzon Genomics SA stock, see the ES:ORY Stock Forecast page.

Oryzon Genomics Advances Phase III Trial for BPD Treatment

Oryzon Genomics has submitted the protocol for its Phase III PORTICO-2 clinical trial to the FDA, aiming to evaluate the efficacy of vafidemstat in treating Borderline Personality Disorder (BPD). This trial seeks to address the unmet medical need of aggression in BPD, building on promising results from previous studies, and marks a significant advancement for Oryzon in the neuropsychiatry field.

The most recent analyst rating on (ES:ORY) stock is a Buy with a EUR2.30 price target. To see the full list of analyst forecasts on Oryzon Genomics SA stock, see the ES:ORY Stock Forecast page.

Oryzon Genomics Announces 2025 Shareholders Meeting

Oryzon Genomics SA has announced the convening of its Ordinary General Meeting of Shareholders, scheduled for June 27, 2025, in Madrid. The meeting will address several key agenda items, including the approval of the annual accounts and management report for the fiscal year ending December 31, 2024, and the application of the fiscal year’s results. This meeting is significant for stakeholders as it will cover crucial financial and operational decisions that could impact the company’s strategic direction and shareholder interests.

The most recent analyst rating on (ES:ORY) stock is a Buy with a EUR2.30 price target. To see the full list of analyst forecasts on Oryzon Genomics SA stock, see the ES:ORY Stock Forecast page.

Oryzon Genomics Strengthens Financial Position and Advances Clinical Trials in Q1 2025

Oryzon Genomics reported a net loss of €1.7M for Q1 2025, aligning with its long-term product development strategy. The company strengthened its financial position with a €30M capital increase and is preparing for a Phase III trial of vafidemstat for Borderline Personality Disorder. Additionally, Oryzon is advancing its oncology trials and expects a significant grant to boost its therapeutic development programs.

Oryzon Genomics Secures €13.26 Million for VANDAM Project under IPCEI

Oryzon Genomics S.A. has been granted a non-refundable aid of approximately €13.26 million from the Med4Cure project, the first Important Project of Common European Interest (IPCEI) in the healthcare sector. This funding will support the VANDAM project, covering 64% of its total budget, and will enable Oryzon to accelerate the clinical development of its epigenetic agents, vafidemstat and iadademstat, for treating rare diseases and hard-to-treat cancers, thereby strengthening its financial position and enhancing its mental health program.